Clarify the Role of Opzelura for Eczema
December 2021
Opzelura (ruxolitinib) 1.5% cream will be the first topical Janus kinase (JAK) inhibitor approved for mild to moderate eczema.
It suppresses cytokines to improve itching and inflammation.
Opzelura is thought to be safer than oral JAK inhibitors (Xeljanz, etc)...since it seems to have less than 10% systemic absorption.
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote